https://www.socictopen.socict.org/files/original/e43e5cb838a6e3e70e7218933ac01583.pdf 1e28bba8ded9e4e61b614bfa6cda9777 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials Creator An entity primarily responsible for making the resource Eugenie R. Lumbers, Eugenie R. Lumbers, Eugenie R. Lumbers, Sarah J. Delforce, Sarah J. Delforce, Sarah J. Delforce, Kirsty G. Pringle, Kirsty G. Pringle, Kirsty G. Pringle, Gary R. Smith Description An account of the resource Angiotensin-converting enzyme 2 (ACE2) is the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from acute respiratory distress syndrome (ARDS) and acute myocarditis and arrhythmias, because it breaks down Angiotensin II, which has inflammatory effects in the lung and heart as well as in the kidney. When SARS-CoV-2 binds to ACE2, it suppresses it, so this protective action of ACE2 is lost. Death from COVID-19 is due to ARDS and also heart failure and acute cardiac injury. Drugs that prevent the inflammatory actions of Angiotensin II (i.e., Angiotensin receptor blockers, ARBs) prevent acute lung injury caused by SARS-CoV. Clinical trials are underway to test the risks and benefits of ARBs and angiotensin-converting enzyme inhibitors (ACEIs) in COVID-19 patients requiring hospitalization. Other potential treatments are also discussed. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource covid-19, SARS-CoV-2, ACE2, cardiovascular disease, Lung injury, renin-angiotensin system (RAS) Identifier An unambiguous reference to the resource within a given context 10.3389/fmed.2020.00248 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Medicine (General)